Evaluating the combination of Abilify Maintena and Rexulti in treating schizophrenia
Real-life Assessment of Aripiprazole Long-acting Injection (Abilify Maintena) Combined With Brexpiprazole (Rexulti) in Schizophrenia: a Naturalistic Non-interventional Prospective Follow-up Study
This study is testing if combining two medications, Abilify Maintena and Rexulti, can help people with schizophrenia feel better when other treatments haven't worked well enough.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT05169268 on ClinicalTrials.gov |
What this trial studies
The MainRexult study aims to assess the efficacy and tolerability of a combination therapy using Abilify Maintena and Rexulti in patients diagnosed with schizophrenia and related disorders. This observational study focuses on individuals who have been on this combination treatment for up to eight weeks. It seeks to provide insights into the real-life effectiveness of this approach, particularly for patients who have not achieved complete symptom relief with standard treatments. The study is designed to gather empirical evidence to support or refute the benefits of adding brexpiprazole to aripiprazole in managing schizophrenia symptoms.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-65 diagnosed with schizophrenia or related disorders who are currently receiving a combination of Abilify Maintena and brexpiprazole.
Not a fit: Patients under 18 years old or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer a new treatment strategy for patients with schizophrenia who experience residual symptoms despite existing therapies.
How similar studies have performed: While there have been case reports indicating favorable outcomes with this combination therapy, empirical evidence from randomized controlled trials is lacking, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: 18- 65 years old at the time of enrollment * Able to read and communicate in English and/or Chinese * Able to give informed consent * Has been diagnosed to have Schizophrenia (DSM-5 or ICD-10 F20 \[except F20.81\], Schizotypal (Personality) Disorder (DSM-5 or ICD-10 F21), or Schizoaffective Disorder (DSM-5 or ICD-10 F25), (Persistent) Delusional Disorder (DSM-5 or ICD-10 F22), Schizophreniform Disorder (DSM-5 or ICD-10 F20.81), Brief Psychotic Disorder (DSM-5) or Acute and Transient Psychotic Disorder (ICD-10 F23) * Is receiving the combination with Abilify Maintena and brexpiprazole as treatment ≤8 weeks at the time of recruitment Exclusion Criteria: * Age \<18 years old * Unable to read English or Chinese * Unable to give informed consent * Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation (ICD-10 F70-73)
Where this trial is running
Hong Kong
- Queen Mary Hospital — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Albert KK Chung — The University of Hong Kong
- Study coordinator: Albert KK Chung, MBBS
- Email: chungkka@hku.hk
- Phone: 2255 4486
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.